Device type · LAO
Enzyme Immunoassay, Methotrexate
Last checked: Nov 19, 2026Source: openFDAMethods & limitations
Product code
LAO
Clinical Toxicology
Device class
Unclassified
FDA decisions since 2015
3
510(k), De Novo and PMA
Adverse event reports
5
Received Nov 1, 2025 to Nov 19, 2026
How FDA classifies it
- Device type
- Enzyme Immunoassay, Methotrexate
- Product code
- LAO
- Device class
- Unclassified
- Review panel
- Clinical Toxicology
- Specialty
- Laboratory Medicine & Pathology
- FDA record
- Classification database entry for LAO
Latest FDA decisions
- ONLINE TDM Methotrexate510(k)
K233454 · Decided Feb 20, 2024 · 123 days after receipt
Device type: Enzyme Immunoassay, Methotrexate (LAO) · Laboratory Medicine & Pathology
K232017 · Decided Dec 20, 2023 · 166 days after receipt
Device type: Enzyme Immunoassay, Methotrexate (LAO) · Laboratory Medicine & Pathology
- ARK Methotrexate Assay510(k)
K163359 · Decided Aug 18, 2017 · 261 days after receipt
Device type: Enzyme Immunoassay, Methotrexate (LAO) · Laboratory Medicine & Pathology
Reports received
5
Received Nov 1, 2025 to Nov 19, 2026
Malfunction reports
5
100% of reports
Injury reports
0
0.0% of reports
Death reports
0
0.0% of reports
Adverse event reports received per month
By the date FDA received each report, stacked by event type. The newest month is incomplete.
- Malfunction
- Injury
- Death
- Other
View as table
| Month | Malfunction | Injury | Death | Other |
|---|---|---|---|---|
| Dec 23 | 0 | 0 | 0 | 0 |
| Jan 24 | 0 | 0 | 0 | 0 |
| Feb 24 | 0 | 0 | 0 | 0 |
| Mar 24 | 0 | 0 | 0 | 0 |
| Apr 24 | 1 | 0 | 0 | 0 |
| May 24 | 0 | 0 | 0 | 0 |
| Jun 24 | 0 | 0 | 0 | 0 |
| Jul 24 | 0 | 0 | 0 | 0 |
| Aug 24 | 0 | 0 | 0 | 0 |
| Sep 24 | 0 | 0 | 0 | 0 |
| Oct 24 | 0 | 0 | 0 | 0 |
| Nov 24 | 0 | 0 | 0 | 0 |
| Dec 24 | 0 | 0 | 0 | 0 |
| Jan 25 | 0 | 0 | 0 | 0 |
| Feb 25 | 0 | 0 | 0 | 0 |
| Mar 25 | 0 | 0 | 0 | 0 |
| Apr 25 | 1 | 0 | 0 | 0 |
| May 25 | 0 | 0 | 0 | 0 |
| Jun 25 | 0 | 0 | 0 | 0 |
| Jul 25 | 0 | 0 | 0 | 0 |
| Aug 25 | 0 | 0 | 0 | 0 |
| Sep 25 | 0 | 0 | 0 | 0 |
| Oct 25 | 0 | 0 | 0 | 0 |
| Nov 25 | 0 | 0 | 0 | 0 |
| Dec 25 | 0 | 0 | 0 | 0 |
| Jan 26 | 0 | 0 | 0 | 0 |
| Feb 26 | 0 | 0 | 0 | 0 |
| Mar 26 | 0 | 0 | 0 | 0 |
| Apr 26 | 2 | 0 | 0 | 0 |
| May 26 | 0 | 0 | 0 | 0 |
| Jun 26 | 0 | 0 | 0 | 0 |
| Jul 26 | 1 | 0 | 0 | 0 |
| Aug 26 | 0 | 0 | 0 | 0 |
| Sep 26 | 1 | 0 | 0 | 0 |
| Oct 26 | 1 | 0 | 0 | 0 |
| Nov 26 | 0 | 0 | 0 | 0 |
Manufacturers named most often
Last 12 months. Bigger sellers get more reports. This is not a ranking of safety.
Device problems as coded
Last 12 months. FDA's terms. A report can carry several.
- Low Test Results4
- Non Reproducible Results3
- Incorrect Measurement1
Patient problems as coded
Last 12 months. FDA's terms. A report can carry several.
- No Clinical Signs, Symptoms or Conditions5
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Siemens Healthcare Diagnostics, Inc.
Z-1618-2016 · Started Mar 8, 2016 · Posted by FDA May 6, 2016
Reason given: Siemens Healthcare Diagnostics confirmed that Syva Emit Methotrexate Application (DVMTX.1) for Dimension Vista System does not meet On-Board Stability claim of 20 hours. Testing using reagent at the end of the 20 hours On-Board Stability has shown that values of methotrexate for patient and quality control samples...
Cause as FDA categorized it: Unknown/Undetermined by firm
Abbott Diagnostic International, Ltd.
Z-1056-2007 · Started Mar 20, 2007 · Posted by FDA Jul 20, 2007
Reason given: Incorrect configuration: kits contain reagent bottles in the order S-W-T-P instead of the correct order, W-S-T-P.
Cause as FDA categorized it: Other
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.